GlassScriptPhysician profile
Emanuel L Javate
NPI 1194819524
$2,299.11
in general payments reported to CMS, 2019-2025
33 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $341 · 2021: $478 · 2022: $447 · 2023: $337 · 2024: $152 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.65 | 2019-2023 | |
| Daiichi Sankyo INC. | $189.89 | 2020-2021 | |
| Hologic Sales and Service, LLC | $122.66 | 2019-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Pfizer INC. | $120.28 | 2020-2023 | |
| Astellas Pharma US INC | $114.62 | 2023-2024 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $92.95 | 2021-2022 | |
| Gynesonics, INC. | $86.54 | 2021-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $83.98 | 2021-2023 | Slynd |
| Avion Pharmaceuticals | $64.65 | 2021-2023 | Balcoltra |
| Evofem Biosciences, INC. | $62.81 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $58.01 | 2023-2025 | Myfembree |
| Allergan, INC. | $56.99 | 2019-2020 | |
| Organon LLC | $56.66 | 2021-2022 | |
| Medtronic, INC. | $52.70 | 2023-2025 | Truclear |
| Mayne Pharma Commercial LLC | $52.40 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $48.35 | 2025 | Genexpert |
| Channel Medsystems, INC. | $43.13 | 2023 | |
| Merck Sharp & Dohme LLC | $43.07 | 2020-2021 | |
| Sage Therapeutics, LLC | $40.62 | 2021-2022 | |
| Coopersurgical, INC. | $40.21 | 2021-2024 | Paragard T 380a |
| Meditrina | $33.50 | 2023-2025 | |
| Intuitive Surgical, INC. | $33.18 | 2022 | |
| Boston Scientific Corporation | $31.56 | 2025 | Axonics |
| Therapeuticsmd, INC. | $28.03 | 2021-2022 | |
| Optumhealth Care Solutions, LLC | $25.90 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Bayer Healthcare Pharmaceuticals INC. | $23.26 | 2023 | |
| Dexcom, INC. | $23.10 | 2025 | Dexcom G6 Transmitter |
| Minerva Surgical, INC | $18.58 | 2022 | |
| Shield Therapeutics INC | $15.40 | 2023 | Accrufer |
| Ethicon US, LLC | $14.28 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.83 | 2021 | |
| Renovia INC | $12.32 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emanuel Javate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.